Session Abstract – PMWC 2020 Silicon Valley


A wealth of data now indicates that inhibiting amyloid infiltration can prevent heart failure and lead to significant improvement in quality of life measures, to an otherwise an aggressive, rapidly progressing, debilitating and fetal disease. This session will review two different therapeutics approaches, a gene silencing drug that interferes with specific messenger RNA to block the production of the protein causing the disease, and a small molecule approach.

 Session Chair Profile

M.D., VP, Medicine Team Lead – Amyloid & Rare Neuro, Pfizer Inc.

Biography
Dr. See Tai leads cross-functional medicine teams from Proof of Concept to First Major Approval, and co-leads through end of lifecycle development activities. She is also responsible for strategic clinical planning for early stage development candidates and technical due diligence for business development opportunities. Sandi has 14 years of experience in the pharmaceutical industry in medical affairs and clinical development at Wyeth Pharmaceuticals and Pfizer Inc. She has worked across multiple therapeutic areas, although her main focus has been kidney disease. Prior to joining the pharmaceutical industry, Sandi was Assistant Professor of Pediatrics at Drexel University College of Medicine and Attending Physician in Pediatric Nephrology at St. Christopher’s Hospital for Children, Philadelphia, where she had completed her General Pediatrics residency and Pediatric Nephrology fellowship. She received her MD from Tufts University School of Medicine.